MIG Fonds has successfully sold its stake in biocrates life sciences AG to Bruker Corporation, marking a significant strategic acquisition in the field of metabolomics.

Information on the Target

biocrates life sciences AG, based in Innsbruck, Austria, is a global leader in mass spectrometry-based quantitative metabolite analysis. The company provides a range of kits, software, and services that facilitate standardized metabolomics practices. Its innovative products are utilized in hundreds of laboratories worldwide, empowering researchers to measure over 1,800 biomarkers from a single drop of blood. This acquisition by Bruker Corporation marks a pivotal moment for biocrates and validates the company's previous achievements in the field.

The partnership with Bruker enhances the latter’s existing mass spectrometry solutions for metabolomics, allowing biocrates to support Bruker’s expansion into the multiomics sector effectively.

Industry Overview in Austria

The biotechnology industry in Austria has been experiencing steady growth over the past several years, driven by advancements in research, technology, and innovation. The country is home to numerous dynamic startups and established companies that are mak